Logo image of AELIS.PA

AELIS FARMA SAS (AELIS.PA) Stock Price, Quote, News and Overview

EPA:AELIS - Euronext Paris - Matif - FR0014007ZB4 - Common Stock - Currency: EUR

1.41  -0.04 (-2.76%)

AELIS.PA Quote, Performance and Key Statistics

AELIS FARMA SAS

EPA:AELIS (3/7/2025, 7:00:00 PM)

1.41

-0.04 (-2.76%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High13.5
52 Week Low1.41
Market Cap19.33M
Shares13.71M
Float13.71M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE0.48
Earnings (Next)N/A N/A
IPO02-18 2022-02-18


AELIS.PA short term performance overview.The bars show the price performance of AELIS.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

AELIS.PA long term performance overview.The bars show the price performance of AELIS.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AELIS.PA is 1.41 EUR. In the past month the price decreased by -36.49%. In the past year, price decreased by -89.52%.

AELIS FARMA SAS / AELIS Daily stock chart

AELIS.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B

About AELIS.PA

Company Profile

Aelis Farma SA engages in the research and development of pharmaceutical products. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 26 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.

Company Info

AELIS FARMA SAS

Neurocentre Francois Magendie 146 Rue Leo, Saignat

Bordeaux NOUVELLE-AQUITAINE FR

Employees: 26

Company Website: https://www.aelisfarma.com/

Investor Relations: http://www.aelisfarma.com/investors

Phone: 33557573770

AELIS FARMA SAS / AELIS.PA FAQ

What is the stock price of AELIS FARMA SAS today?

The current stock price of AELIS.PA is 1.41 EUR. The price decreased by -2.76% in the last trading session.


What is the ticker symbol for AELIS FARMA SAS stock?

The exchange symbol of AELIS FARMA SAS is AELIS and it is listed on the Euronext Paris - Matif exchange.


On which exchange is AELIS.PA stock listed?

AELIS.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for AELIS FARMA SAS stock?

10 analysts have analysed AELIS.PA and the average price target is 9.28 EUR. This implies a price increase of 558.3% is expected in the next year compared to the current price of 1.41. Check the AELIS FARMA SAS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AELIS FARMA SAS worth?

AELIS FARMA SAS (AELIS.PA) has a market capitalization of 19.33M EUR. This makes AELIS.PA a Nano Cap stock.


How many employees does AELIS FARMA SAS have?

AELIS FARMA SAS (AELIS.PA) currently has 26 employees.


What are the support and resistance levels for AELIS FARMA SAS (AELIS.PA) stock?

AELIS FARMA SAS (AELIS.PA) has a resistance level at 1.77. Check the full technical report for a detailed analysis of AELIS.PA support and resistance levels.


Is AELIS FARMA SAS (AELIS.PA) expected to grow?

The Revenue of AELIS FARMA SAS (AELIS.PA) is expected to decline by -63.24% in the next year. Check the estimates tab for more information on the AELIS.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AELIS FARMA SAS (AELIS.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AELIS FARMA SAS (AELIS.PA) stock pay dividends?

AELIS.PA does not pay a dividend.


What is the Price/Earnings (PE) ratio of AELIS FARMA SAS (AELIS.PA)?

AELIS FARMA SAS (AELIS.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.53).


AELIS.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

AELIS.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA. The financial health of AELIS.PA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AELIS.PA Financial Highlights

Over the last trailing twelve months AELIS.PA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS decreased by -29.01% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -17.92%
ROE -35.5%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%-108.95%
Sales Q2Q%-40.22%
EPS 1Y (TTM)-29.01%
Revenue 1Y (TTM)36%

AELIS.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to AELIS.PA. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of -30.17% and a revenue growth -63.24% for AELIS.PA


Ownership
Inst Owners1.67%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts82
Price Target9.28 (558.16%)
EPS Next Y-30.17%
Revenue Next Year-63.24%